China-based Acotec Scientific Holdings Ltd (HKG: 6669) has announced that it has received marketing approvals from the Ministry of Health, Labour and Welfare of Japan and the Thailand Food and Drug Administration for its Vericor-14 microcatheter. This regulatory clearance marks a significant milestone for the company’s product, which can now be utilized in percutaneous intervention surgery for coronary arteries and peripheral blood vessels.
Expanding the Use of Vericor-14 Microcatheter
The Vericor-14 microcatheter is designed to target lesion sites in narrow blood vessels, guide guide wires, and provide channels for exchanging guide wires and delivering physiological saline or diagnostic contrast agents. The product’s approval in Japan and Thailand broadens its potential applications and patient reach in the field of interventional cardiology and vascular surgery.
Implications for Acotec Scientific Holdings
The marketing approvals from these Asian regulatory bodies not only validate the safety and efficacy of the Vericor-14 microcatheter but also open up new markets for Acotec Scientific Holdings. This expansion is expected to contribute to the company’s growth and strengthen its position as a provider of innovative medical devices in the region.-Fineline Info & Tech
